MOG (35-55) Peptide: Foundation for Autoimmune Encephalomyelitis Models

Executive Summary: MOG (35-55) is a truncated peptide from human myelin oligodendrocyte glycoprotein, widely used to induce experimental autoimmune encephalomyelitis (EAE), mimicking multiple sclerosis (MS) in animal models. Its immunogenicity ensures reliable T and B cell activation and demyelination upon administration with adjuvants in susceptible strains. The peptide’s solubility profile (≥32.25 mg/mL in water, ≥86 mg/mL in DMSO) and strict storage parameters are critical for experimental reproducibility (APExBIO product info). Evidence supports its role in modulating oxidative stress and matrix remodeling in EAE pathogenesis (Xu et al., 2025).

Biological Rationale

MOG (35-55) corresponds to amino acids 35 to 55 of the myelin oligodendrocyte glycoprotein, a CNS-specific member of the immunoglobulin superfamily. Its sequence is highly conserved and displayed on the outermost lamellae of CNS myelin, making it accessible to autoreactive lymphocytes. This accessibility underlies its capacity to elicit robust, reproducible autoimmune responses in susceptible mouse strains (see benchmark review).

When combined with complete Freund's adjuvant (CFA), MOG (35-55) acts as a potent autoantigen, triggering EAE, the principal animal model for MS. The resultant pathology—perivascular inflammation, demyelination, and neurological deficit—closely resembles relapsing-remitting and chronic forms of human MS (contextual insights here).

Mechanism of Action of MOG (35-55) Peptide

MOG (35-55) administration induces a break in immune tolerance by mimicking endogenous myelin antigens. The peptide is processed and presented by MHC class II molecules on antigen-presenting cells, leading to the activation of autoreactive CD4+ T cells. These T cells migrate into the CNS, where they orchestrate inflammatory cascades that drive demyelination and neuronal injury. B cell responses and the generation of anti-MOG antibodies further amplify tissue damage. Studies demonstrate that the peptide’s encephalitogenicity is maximal in C57BL/6 and NOD/Lt mice, as well as in HLA-DR2 transgenic models, aligning with MS susceptibility loci (mechanistic overview).

Recent research highlights the role of interferon signaling in EAE pathogenesis. Notably, PARP7 mono-ADP-ribosylates STAT1/STAT2, promoting their autophagic degradation. Inhibition of PARP7 stabilizes STAT1/STAT2, restores type I interferon signaling, and relieves EAE symptoms, emphasizing the utility of MOG (35-55) in dissecting immune regulatory pathways (Xu et al., 2025).

Evidence & Benchmarks

• MOG (35-55) reliably induces EAE with clinical, histological, and immunological fidelity to human MS when administered with CFA in C57BL/6 mice (APExBIO product info).
• Solubility is ≥32.25 mg/mL in water and ≥86 mg/mL in DMSO, but it is insoluble in ethanol (product data).
• Typical in vivo dosing for EAE induction ranges from 50 to 150 μg per mouse, subcutaneously, with 48-hour in vitro incubation at concentrations up to 50 μg/mL (APExBIO).
• MOG (35-55) administration results in dose-dependent decreases in protein concentration and increases in NADPH oxidase and MMP-9 activities, correlating with oxidative stress and matrix remodeling in EAE (Xu et al., 2025).
• PARP7 inhibition in MOG (35-55)-induced EAE models stabilizes STAT1/STAT2 and alleviates disease symptoms by restoring interferon signaling (Xu et al., 2025).

Applications, Limits & Misconceptions

MOG (35-55) is the gold-standard inducer for experimental autoimmune encephalomyelitis and is essential for preclinical MS research. Its defined sequence allows for batch-to-batch reproducibility, making it suitable for mechanistic, therapeutic, and neuroinflammation assays. Studies have leveraged this peptide to investigate immune modulation, neurodegeneration, and the efficacy of novel interventions targeting interferon and PARP pathways.

However, MOG (35-55) is not universally applicable to all rodent strains or all forms of demyelinating disease. Its efficacy depends on genetic background, adjuvant selection, and precise dosing. It does not model progressive MS without additional environmental or genetic modifiers. The peptide does not directly induce disease in rats or non-human primates under standard protocols.

Common Pitfalls or Misconceptions

• Strain specificity: MOG (35-55) does not reliably induce EAE in all mouse strains; susceptibility is highest in C57BL/6 and NOD/Lt mice (product info).
• Solubility errors: Attempting to dissolve MOG (35-55) in ethanol fails; only water or DMSO at specified concentrations yield usable solutions (spec sheet).
• Storage lapses: Peptide degradation occurs with repeated freeze-thaw or storage above -20°C; always store desiccated and use promptly (vendor recommendations).
• Protocol transfer: Protocols optimized for other myelin peptides (e.g., PLP139-151) may not translate directly due to different immunogenicity profiles.
• Pathology scope: The MOG (35-55) model reflects demyelinating, not axonal, pathology unless combined with specific adjuncts or genetic backgrounds.

Workflow Integration & Parameters

• Peptide preparation: Dissolve MOG (35-55) at ≥32.25 mg/mL in sterile water or ≥86 mg/mL in DMSO. For working solutions, dilute to 0.50 mg/mL in sterile water, using warming and ultrasonic shaking as needed (APExBIO).
• Storage: Store stock solutions desiccated at -20°C. Avoid repeated freeze-thaw cycles.
• In vitro use: Typical concentrations range from 0–50 μg/mL, with 48-hour incubation for T cell activation or recall proliferation assays (Xu et al., 2025).
• In vivo induction: Administer 50–150 μg subcutaneously in CFA for EAE induction. Monitor for clinical signs daily.
• Vendor verification: Use products from established suppliers such as APExBIO to ensure batch consistency, as highlighted in practical guidance.

Conclusion & Outlook

MOG (35-55) remains the benchmark for autoimmune encephalomyelitis research, underpinning advances in multiple sclerosis modeling and immunopathology. Its defined sequence and robust immunogenicity facilitate reproducible, interpretable neuroinflammation assays. Integration with recent molecular insights, such as the impact of PARP7 inhibition on interferon signaling, positions this peptide at the forefront of translational MS research (Xu et al., 2025). As new immune-modulatory mechanisms emerge, MOG (35-55)-based models will continue to inform therapeutic development and mechanistic dissection in neuroimmunology.

This article updates and extends the mechanistic details provided by benchmark reviews and molecular insights articles by integrating the latest findings on interferon signaling and PARP7's role, offering actionable, protocol-level recommendations for laboratory scientists.